Re­gen­eron’s gold­en goose Eylea may stave off biosim­i­lar com­pe­ti­tion un­til 2024 or be­yond

Al­most 10 years have passed since its first FDA ap­proval and Re­gen­eron’s mac­u­lar de­gen­er­a­tion in­jec­tion Eylea con­tin­ues to pile up sales to the tune of about $5 bil­lion per year, or more than half of Re­gen­eron’s an­nu­al rev­enues.

Those bil­lions are not ex­pect­ed to go any­where any­time soon thanks to com­pe­ti­tion, even as No­var­tis sub­sidiary San­doz an­nounced Mon­day that it’s be­gin­ning a Phase III tri­al for an Eylea biosim­i­lar in 460 pa­tients across 20 coun­tries.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.